New Nephrogenic Fibrosing Dermopathy (NFD) & Nephrogenic Systemic Fibrosis (NSF) Diagnosis for Patients with Scleromyxoedema-like Cutaneous Disease with Renal Disease
Nephrogenic Fibrosing Dermopathy (NFD) is a recently recognised fibrosing disorder originally identified as a scleromyxoedema-like cutaneous disease in patients with renal disease. The first case of NFD was identified in March 1997. The condition in 15 cases was published in the medical literature as a scleromyxoedema-like cutaneous disease common in renal dialysis patients. In these cases with renal patients diagnosed with scleromyxoedema-like cutaneous disease, the disease was later renamed to "Nephrogenic Fibrosing Dermopathy" (NFD). In cases where scleromyxoedema-like cutaneous disease occurred in systemic organs (lungs, liver, muscles and the heart) in addition to the skin, the patients with scleromyxoedema-like cutaneous disease were later described as suffering from Nephrogenic Systemic Fibrosis (NSF). Nephrogenic Systemic Fibrosis is an acquired condition that develops in patients with Acute Kidney Injury (AKI), advanced Chronic Kidney Disease (CKD) and dialysis-dependent End-Stage Renal Disease (ESRD) and is characterized by patients with dermal fibrosis.
Since the renaming of the scleromyxoedema-like cutaneous disease in patients with renal disease to Nephrogenic Fibrosing Dermopathy (NFD) and Nephrogenic Systemic Fibrosis (NSF), medical researchers have determined that these diseases did not occur prior to 1997, which corresponds to the introduction of Gadolinium (Gd). For years, radiologists took for granted the safety of Gadolinium contrast agents in terms of their adverse effects to MRI and MRA patients. However, the recent medical studies involving Gadolinium contrast dyes and their side effects can not be ignored anymore. As of December 21, 2006 the FDA has received reports to its Adverse Events Reporting System of 90 patients who developed Nephrogenic Systemic Fibrosis (NSF), or Nephrogenic Fibrosing Dermopathy (NFD), after they received a Gadolinium-based contrast agent for an MRI or MRA; all had moderate to end-stage renal disease and others had kidney failure or renal failure. Patients suffered from severe joint pain, muscle pain, skin rashes, skin irritation, problem with limb mobility, thickening of the skin and other Gadolinium side effects -- many have been described in the scientific literature. These patients developed Nephrogenic Systemic Fibrosis (NSF), or Nephrogenic Fibrosing Dermopathy (NFD), two days to 18 months after undergoing their contrast enhanced MRI or MRA. Many of these Nephrogenic Systemic Fibrosis (NSF), or Nephrogenic Fibrosing Dermopathy (NFD), patients received a dose of Gadolinium-based contrast agent exceeding that recommended in product labeling. Some patients developed NSF or NFD after receiving only one dose. According to most medical studies on NSF, the dose relationship in the development of NSF with higher doses of Gadolinium and possibly the numbers of MRIs that a patient has undertaken increases the risk of NSF. Most cases occur in patients who have received > 0.1mmol/kg dose.
Patients with Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD) may develop large areas or patches of hardened skin or thickened skin with fibrotic nodules and plaques. These areas of thick skin and flexion contractures in the body's extremities can severely limit a patient's range of motion. Nephrogenic Systemic Fibrosis (NSF) resembles scleromyxedema at the histologic (microscopic) level; it shows a proliferation of dermal fibroblasts and dendritic cells, thickened collagen bundles, increased elastic fibers, and deposits of mucin. Symptoms of Nephrogenic Systemic Fibrosis (NSF) can vary from patient to patient as well as the Nephrogenic Systemic Fibrosis (NSF) prognosis.
Nephrogenic Systemic Fibrosis (NSF) Lawsuit
If you had a MRI or a MRA, and a Gadolinium contrast dye, medium or agent was used to enhance the MRI image, and you have been diagnosed with scleromyxoedema-like cutaneous disease in patients with renal disease, then it is possible that your scleromyxoedema-like cutaneous disease was caused in part from the Gadolinium and you may be eligible to collect money damages for your injuries in an individual MRI lawsuit or a national class action lawsuit. Please fill out our Free NSF Lawsuit Evaluation to learn more about your legal rights, or call us Toll Free at 1-800-883-9858.
 Click Here for a Free Lawsuit Case Evaluation |
Nephrogenic Systemic Fibrosis (NSF) Nephrogenic Fibrosing Dermopathy (NFD) Causes of NSF Gadolinium MRI What is Gadolinium? Types of Gadolinium Gadolinium FDA Report NSF Symptoms Test for NSF NSF Treatment Doctor Medical Centers NSF Links MRI Lawsuits NSF Lawsuit NSF Punch Biopsy NSF Registry Contact Us
Gadolinium Contrast Dyes:
Omniscan
(Gadodiamide)
Manufacturer: GE Healthcare
OptiMARK
(Gadoversetamide Injection)
Manufacturer: Mallinckrodt
Manufacturer: Tyco Healthcare
Magnevist
(Gadopentetate Dimeglumine)
Manufacturer: Bayer HealthCare
Manufacturer: Schering AG
Manufacturer: Berlex
ProHance
(Gadoteridol Injection)
Manufacturer: Bracco Diagnostics
MultiHance
(Gadobenate Dimeglumine)
Manufacturer: Bracco Diagnostics
NFD and NSF Symptoms:
• Skin Swelling
• Skin Hardening
• Skin Tightening
• Orange Peel Textured Skin
• Reddened Skin
• Darkened Skin Patches
• Burning Skin
• Itchy Skin
• Yellow Raised Spots on Eyes
• Bone Problems
• Joint Problems
• Muscle Problems
• Stiff Joints
• Problems Moving Arms
• Problems Moving Hands
• Problems Moving Legs
• Problems Moving Feet
• Problems Straightening Arms
• Problems Straightening Hands
• Problems Straightening Legs
• Problems Straightening Feet
• Deep Pain in Hip Bones
• Deep Pain in Ribs
• Muscle Weakness
High Risk Patients Have:
• Kidney Problems
• Kidney Insufficiency
• Kidney Failure
• Renal Failure
• Had Liver Transplantation
• Chronic Liver Disease
